Outcomes.
obesity, infections, renal dysfunction
INS, OBESITY, RECURRENCE, DISEASE, IMPAIRED GLUCOSE TOLERANCE, INFECTIONS, ADVERSE EFFECTS, SECONDARY, ARTERIAL HYPERTENSION, DYSLIPIDEMIA
The study primarily aimed to assess the safety and feasibility of autologous MSC infusions in patients with severe forms of INS. Secondary study objectives included assessing the efficacy of autologous MSC infusions in reducing disease relapses and exposure to immunosuppressive drugs.The secondary efficacy endpoints were recurrence of INS, dose of immunosuppressive therapy to prevent further INS relapses, adverse effects of immunosuppressive therapy (arterial hypertension and need for antihypertensive therapy, obesity and impaired glucose tolerance, dyslipidemia, renal dysfunction, stunted statural growth, infections), and kidney function at baseline and at 1 year after MSC administration.